Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Research Council grant · Running

CLUSTER-TIL Harnessing Heterotypic T Cell Clusters to Boost Til Cancer Therapy

Coordinator
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis, Netherlands
Runs
1 September 2026 to 29 February 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101335229

What the project is doing

In the project's own words, from its summary on CORDIS.

Despite major advances in cancer immunotherapy, most patients still lack durable benefit. Tumor-infiltrating T lymphocyte (TIL) therapy can induce deep cancer remissions, but potency varies and complete clinical responses are limited to 20%. Crucially, although truly tumor-reactive T cells are rare in cancers (<5%), current manufacturing protocols expand TILs in bulk, without inclusion of a selection or enrichment step.

Together, these observations create both a dire clinical need and unique opportunity to augment the impact of this type of immunotherapy, namely by selecting the actively tumor-killing T cells. In our current ERC Advanced project ReverT, we discovered that tumor-killing T cells are strongly enriched in so-called heterotypic cell clusters: tight conjugates of T cells with tumor (melanoma) cells and/or antigen-presenting cells.

We developed an isolation procedure to capture intact clusters straight from clinical cancer specimens from patients. These T cell clusters can be effectively expanded and exhibit a 9-fold increase in tumor-killing activity against patient tumors. This ERC PoC project translates our findings into a “CLUSTER-TIL” manufacturing module, integrating upstream of the standard production pipeline to enable enhanced TIL therapy.

We will develop and optimize a scalable procedure to purify cluster-derived T cells from tumor digests from patients, define quality metrics for tumor reactivity and benchmark to the standard bulk TIL workflow. CLUSTER-TIL will deliver a highly potent, consistent anti-cancer T cell therapy that will be tested in a planned investigator-initiated Phase 2a trial in melanoma. We observe similar clusters in other solid tumor types, enabling expansion to patient groups beyond melanoma.

Furthermore, two patent applications protect the CLUSTER-TIL technology. This PoC will also generate follow-on IP to support a spin-off applying the technology for broader clinical implementation and improved patient outcomes.

Topics

Who is involved

OrganisationCityCountryRole
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek ZiekenhuisAmsterdamNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI